Results 251 to 260 of about 1,897,702 (279)

N-terminally truncated interleukin-38

2016
The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors.
FRAUNHOFER GES FORSCHUNG, JOHANN WOLFGANG GOETHE UNIVERSITÄT FRANKFURT AM MAIN   +1 more
openaire   +1 more source

Assessment of the levels of interleukin-17 and interleukin-38 in thyroid-associated ophthalmopathy patients

International ophtalmology, 2023
Ainur Musakulova, A. Balmukhanova, A. Aubakirova, G. Zhunusova, A. Balmukhanova, J. Issakhanova, T. Saliev, S. Tanabayeva, Ildar Fakhradiyev   +8 more
semanticscholar   +1 more source

Interleukin-38 signaling

Reactome - a curated knowledgebase of biological pathways, 2017
openaire   +1 more source

N-terminally truncated interleukin-38

The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors.
openaire  

A Prospective Study to Assess The Role of Interleukin-38 in Inflammatory Bowel Disease

, 2021
Manjeet K. Sandhu
semanticscholar   +1 more source

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

Lancet, The, 2008
Andrea Rubbert-Roth, César R Ramos-Remus, Rieke E Alten   +2 more
exaly  

Review for "Interleukin‐38: A crucial player in periodontitis"

2023
openaire   +1 more source

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

Lancet, The, 2013
Antoinette Moran, Linda A Dimeglio, Stephen E Gitelman   +2 more
exaly  

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2015
Iain B Mcinnes, Philip J Mease, Bruce W Kirkham   +2 more
exaly  

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
B G Feagan, Julian Panes, Arthur Kaser
exaly